Barby Ingle’s One Pager
We ask chronic pain patient advocate Barby Ingle how she prepares for a clinical encounter.
How We Learn In Medicine
Medical education is concerningly different for practicing physicians compared with medical students.
Faulty Opioid Overdose Data
Initial waves of opioid settlement dollars have been dispensed. Yet we still struggle to define addiction. Unless we refine our ...
Lived Experience is Data
Data on addiction and overdoses are notoriously weak. They're subject to varying interpretations. We need to study the lived experiences ...
To Be a Chronic Pain Advocate
We share our experiences reaching out to and speaking with federal and state legislators while offering nuggets of advice and ...
My Friend, Dr. Ruan
I discuss my growing friendship with Dr. Ruan. It is a bond forged over a united fight for physician rights.
Dr. Ruan Requests Support For Another Writ
Dr. Ruan requests Amicus Briefs for an upcoming Petition for Writ of Certiorari.
Ruan Invalidates Moore
Dr. Ruan argues the Supreme Court ruling in Ruan invalidates prior interpretations of the CSA.
How They Discredit You
We muse on the importance of retaining credibility when standing up to false opioid narratives.
Narratives on the Opioid Crisis
We propose new rules for journalists to integrate statistics on opioids and related overdoses into their stories.
Thank you, AHCJ!
We reflect on our experiences at the recent Association of Health Care Journalists conference in St. Louis.
Confronting My Fears
I discuss my continuing struggles to overcome self-doubt and share some techniques that have proved effective.
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more